Abraxis Bioscience, Inc.
http://www.abraxisbio.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Abraxis Bioscience, Inc.
Strong Sales, Deals Propel China Biotechs To 2023 Profitability
Strong sales growth and licensing activity in 2023 helped multiple Chinese biotechs to a solid profit performance, some moving into the black for the first time.
Deal Watch: Lilly Sends European Commercial Rights For Two Migraine Drugs To Organon
Plus deals involving Biocytogen, Neurocrine and Ona, Aeterna Zentaris/Ceapro, Teva/Biolojic Design, Pathos AI/Rain Oncology, Inhibitor Therapeutics/Johns Hopkins and more.
Milestone Taking Etripamil Into Phase III For AFib Based On Phase II Success
The company’s calcium channel blocker nasal spray rapidly slowed atrial fibrillation patients’ heart rates, showing potential to be an at-home replacement for emergency room-administered treatment.
EMA Backs Approval Of Santhera’s Agamree, Pfizer’s Elrexfio & Several Other New Drugs
Four new orphan medicines were among the products recommended for pan-EU marketing approval by the European Medicines Agency this week.
Company Information
- Other Names / Subsidiaries
-
- Shimoda Biotech Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice